Copenhagen, Denmark — August 7, 2025 — Leads & Copy — Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) to present its financial results for the second quarter of 2025.
President and CEO Adam Steensberg, CFO Henriette Wennicke, CMO David Kendall, and CCO Eric Cox will participate in the call, which will include a Q&A session.
A live, listen-only audio webcast and slide presentation will be available at https://edge.media-server.com/mmc/p/w964yrhw. Registration for telephone dial-in information and a unique access PIN is available at https://register-conf.media-server.com/register/BI38dbf0632d0e4bcfa7d2cd384405fa1f. Participants are advised to register approximately 10 minutes before the start. A recording will be available on Zealand Pharma’s website.
Zealand Pharma A/S (Nasdaq: ZEAL) is focused on the discovery and development of peptide-based medicines. More than 10 of their drug candidates have advanced into clinical development, with two reaching the market and three in late-stage development. The company has development and commercial partnerships with several pharma companies.
Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, and has a presence in the U.S.
Contacts:
Adam Lange (Investors)
Vice President, Investor Relations
alange@zealandpharma.com
Neshat Ahmadi (Investors)
Investor Relations Manager
neahmadi@zealandpharma.com
Anna Krassowska, PhD (Investor and Media)
Vice President, Investor Relations & Corporate Communications
akrassowska@zealandpharma.com
Source: Zealand Pharma A/S
